Airways Type-2 Related Disorders: Multiorgan, Systemic or Syndemic Disease?
Open accessThe DOI matches its Crossref record; 139 of the 139 references it cites were found in a registry or an index.
Abstract
Chronic rhinosinusitis (CRS) has recently undergone a significant paradigm shift, moving from a phenotypical classification towards an “endotype-based” definition that places more emphasis on clinical and therapeutic aspects. Similar to other airway diseases, like asthma, most cases of CRS in developed countries exhibit a dysregulated type-2 immune response and related cytokines. Consequently, the traditional distinction between upper and lower airways has been replaced by a “united airway” perspective. Additionally, type-2 related disorders extend beyond respiratory boundaries, encompassing conditions beyond the airways, such as atopic dermatitis. This necessitates a multidisciplinary approach. Moreover, consideration of possible systemic implications is crucial, particularly in relation to sleep-related breathing diseases like Obstructive Sleep Apnoea Syndrome (OSAS) and the alteration of systemic inflammatory mediators such as nitric oxide. The trends in epidemiological, economic, and social burden are progressively increasing worldwide, indicating syndemic characteristics. In light of these insights, this narrative review aims to present the latest evidence on respiratory type-2 related disorders, with a specific focus on CRS while promoting a comprehensive perspective on the “united airways”. It also introduces a novel concept: viewing these conditions as a multiorgan, systemic, and syndemic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“diseases are not evenly dispersed across populations but rather tend to cluster in disadvantaged groups that suffer elevated rates of multimorbidity”
From Is Pollution the Primary Driver of Infectious Syndemics? (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“such clustering increases opportunities for disease interactions across various biological and psychological pathways”
From Is Pollution the Primary Driver of Infectious Syndemics? (2024) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The TSLP alarmin produced by keratinocytes subjected to stress, allergens, or pathogens, causes the activation of dendritic cells and the secretion of chemokines, which attract type 2 helper T lymphocytes (Th2) to the skin, releasing pro-allergenic cytokines (type 2 inflammation cytokines, such as IL-4, IL-13, IL-5, IL-31).”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among asthmatic patients, there is a prevalence of approximately 40% of CRS with polyposis, and AD is more common among these patients with CRS with nasal polyposis, compared to those with CRS without polyposis.”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the context of chronic rhinosinusitis (CRS), damage to the upper airway epithelial barrier initiates and perpetuates type 2 inflammation, and environmental factors such as viruses and other stimuli generate alarmins such as TSLP, IL-25, and IL-33, which increase nasal inflammation.”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [18]
Experimental — accuracy not yet measured
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Position Paper on Rhinosinusitis and Nasal Polyps 2020
Fokkens, W. J., Lund, V. J., Hopkins, C., Hellings, P. W., Kern, R., Reitsma, S., Toppila-Salmi, S., Bernal-Sprekelsen, M., Mullol, J., Alobid, I., et al. (2020) · Rhinology journal · doi:10.4193/rhin20.600 · Cited by 5,882
Hay fever, hygiene, and household size.
Strachan, D. P. (1989) · BMJ · doi:10.1136/bmj.299.6710.1259 · Cited by 5,054
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma
Chung, K. F., Wenzel, S. E., Brozek, J. L., Bush, A., Castro, M., Sterk, P. J., Adcock, I. M., Bateman, E. D., Bel, E. H., Bleecker, E. R., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00202013 · Cited by 3,926 · cited 1×
“In a recent real-life analysis, severe asthma, based on the European Respiratory Society/American Thoracic Society guidelines (ERS/ATS) [53], demonstrated a frequent association with several type-2 related pathways, including higher blood and sputum eosinophils, indicating that treatments targeting…”
MethodAllergic Rhinitis and Its Impact on Asthma
Bousquet, J., van Cauwenberge, P., & Khaltaev, N. (2001) · Journal of Allergy and Clinical Immunology · doi:10.1067/mai.2001.118891 · Cited by 3,588
Beasley, R. (1998) · The Lancet · doi:10.1016/s0140-6736(97)07302-9 · Cited by 3,389
Dweik, R. A., Boggs, P. B., Erzurum, S. C., Irvin, C. G., Leigh, M. W., Lundberg, J. O., Olin, A.-C., Plummer, A. L., & Taylor, D. R. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.9120-11st · Cited by 2,539
Constitution of the World Health Organization
(1946) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.36.11.1315 · Cited by 2,519 · cited 1×
““Health” was defined in 1948 by the World Health Organization as a state of complete physical, mental, emotional, and social well-being and not only the absence of disease or infirmity [5].”
BackgroundPrevalence of sleep-disordered breathing in the general population: the HypnoLaus study
Heinzer, R., Vat, S., Marques-Vidal, P., Marti-Soler, H., Andries, D., Tobback, N., Mooser, V, Preisig, M., Malhotra, A., Waeber, G., et al. (2015) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00043-0 · Cited by 2,481 · cited 1×
“…studies (such as the recent “HypnoLaus”) have shown that the prevalence of moderate-to-severe OSA, also due to the increased sensitivity of modern diagnostic facilities, stands up to 23.4% in women and 49.7% in men, enhancing the public awareness of the global burden of this chronic condition [91].”
BackgroundInfluentialMepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Ortega, H. G., Liu, M. C., Pavord, I. D., Brusselle, G. G., FitzGerald, J. M., Chetta, A., Humbert, M., Katz, L. E., Keene, O. N., Yancey, S. W., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403290 · Cited by 2,322 · cited 1×
“Moreover, in patients with a peripheral eosinophil count ≥ 500 cells/ µ L, mepolizumab reduced exacerbation rates by 74 and 79% relative to placebo with SC and IV doses, respectively [66].”
BackgroundDupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma
Castro, M., Corren, J., Pavord, I. D., Maspero, J., Wenzel, S., Rabe, K. F., Busse, W. W., Ford, L., Sher, L., FitzGerald, J. M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804092 · Cited by 1,986 · cited 1×
“…inhibitors of these particular pathways, such as omalizumab (Xolair ® , Genentech USA, Inc., San Francisco, CA, USA and Novartis Pharmaceuticals Corporation, Tokyo, Japan) a recombinant humanized anti-IgE monoclonal antibody and others specific for type-2 cytokines (IL-4, IL-5, and IL-13) [62,63].”
Background
Cited by
Update on the pathogenesis of atopic dermatitis.
Criado, P. R., Miot, H. A., Bueno-Filho, R., Ianhez, M., Criado, R. F. J., & de Castro, C. C. S. (2024) · Anais brasileiros de dermatologia · doi:10.1016/j.abd.2024.06.001 · Cited by 66
Personalized COPD Care: The Future of Precision-Based Therapies
Appleton, L. K., Hanania, N. A., & Adrish, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216339 · Cited by 18
“…rhinitis, atopic dermatitis, asthma, and nasal polyposis, suggesting that T2 inflammation is far more systemically pathologic beyond the lungs [24,25]. airway and other organ systems including allergic rhinitis, atopic dermatitis, asthma, and nasal polyposis, suggesting that T2 in fl ammation…”
BackgroundPace, G. M., Giombi, F., Pirola, F., Cerasuolo, M., Heffler, E. M., Paoletti, G., Puggioni, F., Mercante, G., Spriano, G., & Malvezzi, L. (2024) · Annals of Otology Rhinology & Laryngology · doi:10.1177/00034894241300812 · Cited by 12
Self-citationPiazzetta, G. L., Lobello, N., Pelaia, C., Preianò, M., Lombardo, N., & Chiarella, E. (2025) · Tissue Barriers · doi:10.1080/21688370.2025.2470477 · Cited by 10
“42 In this context, recent studies suggest that Korean Red Ginseng (Panax ginseng Meyer) may have potential benefits for improving ciliogenesis and ciliary function.”
Is Pollution the Primary Driver of Infectious Syndemics?
Singer, M. (2024) · Pathogens · doi:10.3390/pathogens13050370 · Cited by 8
Connecting the Airways: Current Trends in United Airway Diseases
Bondi, B., Buscema, M., Marco, F. D., Conti, C., Caviglia, A., Fucci, L., Riccio, A., Mincarini, M., Ottoni, M., Braido, F., et al. (2026) · Journal of Personalized Medicine · doi:10.3390/jpm16010021 · Cited by 8
“Therefore, it can be deduced from here that every patient with rhinitis/rhinosinusitis should also be evaluated for the presence of lung diseases (and vice versa) [3,10–12]. https://doi.org/10.3390/jpm16010021 This frequent coexistence is found principally in severe disease phenotypes.”
InfluentialHeffler, E. M., Blasi, F., Paggiaro, P., & Canonica, G. W. (2025) · Advances in Therapy · doi:10.1007/s12325-024-03071-w · Cited by 8
Self-citationMoon, S., Moon, S., Lee, S., Kim, G., Koo, M., Cho, H., Kim, C., & Rha, M. (2025) · Allergy · doi:10.1111/all.16652 · Cited by 7
“Several noninvasive markers have been suggested to identify the presence of T2 inflammation [22, 23].”
Awad, B. I., Aldokhail, L., Alotaibi, E. M., Asiri, H. M., Asery, Y. A., Nahhas, N. K., & Halawani, M. (2025) · Ear Nose & Throat Journal · doi:10.1177/01455613251378726 · Cited by 6
Measuring Nasal Airway Resistance to Personalize Surgery for Nasal Obstruction in OSA Patients
Lunardi, G., Giombi, F., Pace, G. M., Cerasuolo, M., Spriano, G., & Malvezzi, L. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15120608 · Cited by 6
Self-citationBiologics Use in Eosinophilic Lung Disease: Controversies and Consensus
de Llano, L. P., Dacal-Rivas, D., Pavord, I. D., ASLAM, M. M. S., & Lugogo, N. L. (2026) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2026.01.022 · Cited by 4
Giombi, F., Pace, G. M., Mari, G., Cerasuolo, M., Sandri, G., Cerri, L., Heffler, E. M., Paoletti, G., Puggioni, F., Mercante, G., et al. (2025) · Ear Nose & Throat Journal · doi:10.1177/01455613251350508 · Cited by 3
Self-citationLee, J., Ali, M. A., Kim, S. W., & Kim, S. (2026) · Otolaryngology · doi:10.1002/ohn.70108 · Cited by 2
“6 The variability in FeNO levels among ECRS patients, as evidenced by the wide CIs in some studies, may re fl ect the heterogeneity of FeNO measurement methods across studies.”
Giombi, F., Mercante, G., Nappi, E., Marzio, V., & Malvezzi, L. (2024) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000001057 · Cited by 2
Self-citationZhai, J.-H., Zhu, L., Chen, S.-Q., Jian, X., & Chen, C. (2026) · Sleep and Biological Rhythms · doi:10.1007/s41105-026-00641-z · Cited by 1
Zou, P., Fan, Y., Xie, C., Xia, W., Liu, Y., 陶沛, Huang, Y., Wang, L., & Ai, T. (2026) · Journal of Asthma and Allergy · doi:10.2147/jaa.s620785 · Cited by 1
“…that these two conditions are not isolated pathological events, but rather manifestations of highly intertwined systemic immune dysregulation 3 The development of allergic diseases typically exhibits a significant age-dependent phenotypic variations—originating from impaired skin and…”
Paoletti, G., Cavaglià, E., Biase, A. D., & Bona, D. D. (2025) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000001087 · Cited by 1
Self-citationEditorial: pharmacotherapy and evidence-based medicine
Paoletti, G., Buta, F., & Bona, D. D. (2024) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000995
Self-citationCaldirola, D., Daccò, S., Puggioni, F., Crebelli, M., Grassi, M., Alciati, A., Malvezzi, L., Heffler, E. M., & Perna, G. (2025) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2025.112325
Self-citationGioacchino, M. D., Bagnasco, D., Braido, F., Buta, F., Caponnetto, P., Carbone, R. G., Cazzola, M., van de Veen, W., Vitis, C. D., Deng, L., et al. (2026) · Exploration of Asthma & Allergy · doi:10.37349/eaa.2026.1009111
Self-citationLv, M., Wang, C., Hong, Y., Ye, F., Cao, X., Zheng, Z., Zhang, E., Liu, J., Jia, A., & Peng, G. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158378
Santoso, B., & Rosmala, D. (2026) · International Journal of Health Science and Technology · doi:10.31101/ijhst.v7i3.4508
Zhan, Z., Xu, T., & Huang, S. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1855307
Moreno‐Luna, R., Jiménez, D. I. M., Alobid, I., del Cuvillo, A., & Sánchez‐Gómez, S. (2026) · Current Allergy and Asthma Reports · doi:10.1007/s11882-026-01287-0 · Cited by 1
“The fate of an initially localized mucosal response may also be shaped by the interplay among host susceptibility, the respiratory exposome, epithelial barrier integrity, the local microbiome and epigenetic regulation [ 31, 40, 54].”
Metabolic Comorbidities in Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis
Roberts, K. A., Gandra, N., Nguyen, S. A., Howser, L. A., Arnold, T. B., Soler, Z. M., & Schlosser, R. J. (2026) · American Journal of Rhinology and Allergy · doi:10.1177/19458924261481207
Predictors of Refractory Primary Chronic Rhinosinusitis Following Endoscopic Sinus Surgery
Khaderi, I. M., Tochigi, K., Barefoot, N. R., Desai, P. J., Cid, E. Q. D., Bootes, K., Omura, K., Tanaka, Y., Klatt‐Cromwell, C. N., Vuncannon, J. R., et al. (2026) · International Forum of Allergy & Rhinology · doi:10.1002/alr.70267
Bizzi, E., Marra, A. M., Manzotti, G., Gidaro, A., Ortolani, V. G. R., Iemoli, E., Borgonovo, L., Asperti, C., Modica, S., Greco, E., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1950211
Metadata
- Authors
- Giombi, F., Pace, G. M., Pirola, F., Cerasuolo, M., Ferreli, F., Mercante, G., Spriano, G., Canonica, G. W., Heffler, E., Ferri, S., Puggioni, F., Paoletti, G., & Malvezzi, L.
- Affiliations
- Humanitas University (IT)
- IRCCS Humanitas Research Hospital (IT)
- Corresponding author
- Pace, Gian Marco
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-01-05
- Volume
- 25
- Issue
- 2
- Pages
- 730
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10815382
- OpenAlex
- W4390617982
- Cited by
- 25
- References
- 139
- Citations by year
- 2026: 11 · 2025: 8 · 2024: 6
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Otorhinolaryngology › Sinusitis and nasal conditions
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Keywords
- chronic rhinosinusitis, Th2 immune response, united airways, endotypes, atopic dermatitis, obstructive sleep apnea, nitric oxide, systemic inflammation, multi-organ disease
- MeSH terms
- Syndemic, Asthma, Humans, Respiration, Sleep Wake Disorders, Cytokines, Sleep Apnea, Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
